Refractory plasma cell neoplasm
diseaseOn this page
Summary
Refractory plasma cell neoplasm (MONDO:0004816) is a cancer and 3 clinical trials. Top therapeutic interventions include arsenic trioxide, sargramostim, and keyhole limpet hemocyanin. A subtype of refractory hematologic cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | refractory plasma cell neoplasm |
| Mondo ID | MONDO:0004816 |
| DOID | DOID:9544 |
| NCIT | C7813 |
| UMLS | C0278620 |
| MedGen | 75844 |
| GARD | 0024112 |
| Is cancer (heuristic) | yes |
Also known as: refractory plasma cell neoplasm
Disease family
This is a subtype of refractory hematologic cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › refractory hematologic cancer › refractory plasma cell neoplasm
Related subtypes (5): refractory hairy cell leukemia, refractory precursor T-lymphoblastic lymphoma/leukemia, refractory anemia with excess blasts in transformation, myelodysplastic syndrome with multilineage dysplasia, refractory cytopenia of childhood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00019097 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Multiple Myeloma |
| NCT00085345 | PHASE2 | WITHDRAWN | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT00112879 | PHASE2 | WITHDRAWN | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ARSENIC TRIOXIDE | 4 | 2 |
| SARGRAMOSTIM | 4 | 1 |
| KEYHOLE LIMPET HEMOCYANIN | 3 | 1 |